 CAMBRIDGE, Mass., Sept. 20, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic BioticTM medicines for the treatment of phenylketonuria PKU. 